be strong, page-11

Hi hammer, welcome to EMS threads.

From the annual report -

"We are now completing the pharmacodynamics studies, biochemistry and parasitology and other evaluations of the patient data. Results will be forwarded to the biostatisticians for analysis and then to a medical writer for compilation into the final clinical report. The report is anticipated to be available by the end of 2012."

I expect that it will occur prior to end of Dec, to ensure that burbagevalley's 'Option 2' doesn't happen.

If SC gets a seat at the malaria conference (in Oz at the end of October), he may have some preliminary results to yak about, which would be cool.

EMS mkt cap is $20M, which I find very low. They've completed the PhIII trials (and the drug is not on trial here the delivery system is). I don't know of another biotech stock on the ASX that is currently in PhIII trails let alone having finished them. The delivery system proved very successful in PhII trials, so there is fair justification that the results being vey positive.

If this thing was on the NASDAQ, the SP would be at least an order of magnitude higher. I guess that says something about the focus of ASX invetsors in the resources area.

EMS posters - hammer edits a daily update on the BIOTECH threads which gives great insight into many of biospecs on the ASX.

bluebush